Biotinylated Human GUCY2C/Guanylyl cyclase C Protein
Catalog No: GUCY2C-HB001
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human GUCY2C/Guanylyl cyclase C Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus. It contains amino acid residues Ser24-Gln430 (UniProt accession: P25092-1).
Product Details
- Molecular Aliases
- Guanylyl cyclase C; GC-C; STAR; GUCY2C; GUC2C; STA receptor; DIAR6; EC 4.6.1; GCC; GUC2CEC 4.6.1.2; MUCIL; EC4.6.1; GUC2CEC4.6.1.2
- Protein Length
- Ser24-Gln430
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 48.8 kDa. Due to glycosylation, the protein migrates to 55-65 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 24 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Biotinylated Human GUCY2C on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human GUCY2C is greater than 95% as determined by SEC-HPLC.
Immobilized Biotinylated Human GUCY2C, His-Avi tag at 0.5μg/ml (100μl/Well) on streptavidin (5μg/ml) precoated plate. Dose response curve for Anti-GUCY2C Antibody, hFc Tag with the EC50 of 3.1ng/ml determined by ELISA. (QC Test)
Background
Guanylyl cyclase C (GUCY2C) has canonical centrality in defense of key intestinal homeostatic mechanisms, encompassing fluid and electrolyte balance, epithelial dynamics, antitumorigenesis, and intestinal barrier function. GUCY2C may represent a new target for anti-obesity pharmacotherapy.
References
- Magee MS, Abraham TS, Baybutt TR, et al. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. Cancer Immunol Res. 2018;6(5):509‐516. doi:10.1158/2326-6066. CIR-16-0362
Have questions about this product?
Our technical team can help with product selection, application questions and order support.